Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2019

View Archived Issues

Suzhou Yunxuan Yiyao Keji Youxian Gongsi discloses CXCR4 antagonists

Why there's no Emgality equality

Combination approach could foil pancreatic tumors

Discovery of novel DS-6930 derivatives by structure-activity relationship analysis

Chemerin involved in tumorigenesis and metastasis of OSCC and may be useful as a serum biomarker

TTC21A biallelic mutations induce asthenoteratospermia

Novel isocytosine deaminase Vcz converts 5-FIC prodrug into toxic 5-FU for cancer therapy

OPKO reports additional phase II results for OPK-88003 in patients with diabetes and obesity

Gilead Sciences and Novo Nordisk to collaborate on clinical trial in NASH

Growth acceleration seen with maralixibat in progressive familial intrahepatic cholestasis

Odevixibat has beneficial effects in phase II trials in Alagille syndrome, biliary atresia

FDA approves Balversa for metastatic bladder cancer

Potential new regenerative strategy identified for OA

Dragonfly Therapeutics patents proteins binding NKG2D, CD16 and a tumor-associated antigen

Ionis Pharmaceuticals synthesizes oligonucleotides targeting Smad7

New data presented from phase III CREDENCE study

CDK19 inhibitors discovered by Stanford University, Chan Zuckerberg Biohub

U.S. Department of Health & Human Services, Lentigen Technology describe CAR T cells targeting CD19

PCAT1 identified as a potential therapeutic target in HNSCC

Sunshine Lake Pharma initiates phase I study of HEC-110114 tablets

Harpoon Therapeutics recruiting patients in phase I/II study of HPN-536

Sorrento Therapeutics expands clinical development program for resiniferatoxin

Zymeworks initiates phase II study of ZW-25 in HER2-expressing metastatic gastroesophageal cancers

First patient dosed in global phase II/III ILLUMINATE study of sepofarsen for LCA10

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...